cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

How MSC Exosomes Are Characterized: Size, Markers, and Sterility

← Back to Research Library

“Characterization” is the laboratory process of measuring what an exosome preparation actually contains. For anyone comparing MSC-derived exosome suppliers, understanding these measurements is the difference between evaluating data and evaluating adjectives. This overview is provided for educational and research purposes only.

Particle size and concentration

A defining feature of exosomes is their size — generally 30–150 nanometers. Methods such as nanoparticle tracking analysis (NTA) measure both the size distribution and the particle concentration of a sample, confirming the population falls in the expected range and quantifying how many particles are present per dose or per milliliter.

Identity and surface markers

Exosomes carry characteristic surface proteins. Marker analysis is used in the literature to help confirm that a preparation is consistent with exosomes rather than other particles or debris. Identity testing is part of distinguishing a characterized material from an unverified one.

Purity and sterility

Beyond identity, a research-grade preparation should be tested for purity and sterility. These results, documented per lot, are part of what a credible supplier reports.

Putting it together: the Certificate of Analysis

Each of these measurements should appear on a per-lot Certificate of Analysis (COA), ideally produced by an independent third-party laboratory. A COA turns characterization from a marketing claim into a verifiable record — which is the entire point of characterization in the first place.

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease and are supplied for research use only. This content is for educational and informational purposes and does not constitute medical advice.

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.